3354 Duffy, Danielle - Thomas Jefferson University
Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Duffy, Danielle

< Back



Danielle Duffy, MD

Contact Dr. Duffy

925 Chestnut Street
Mezzanine Level
Philadelphia, PA 19107

(215) 955-3607
(215) 503-3976 fax

Medical School

University of Pennsylvania School of Medicine - 2002


Hospital of the University of Pennsylvania


University of Pennsylvania School of Medicine
Cardiovascular Diseases, Thomas Jefferson University Hospital

Board Certification

Internal Medicine
Cardiovascular Disease

Hospital Appointment

Thomas Jefferson University Hospital

Expertise & Research Areas

My areas of clinical expertise are complex lipid disorders, cardiovascular prevention, and cardiovascular disease in women. My general research focus is preventive cardiology. My specific interests and ongoing projects involve new therapeutics for HDL and LDL-cholesterol, the use of additional diagnotic testing for cardiovascular risk stratification, and women's cardiovascular prevention.


Lipid disorders 3994 ; preventive cardiology; familial hypercholesterolemia; new therapeutics; women's cardiovascular health


Most Recent Peer-Reviewed Publications

  1. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice
  2. Targeting Lipoprotein (a): an Evolving Therapeutic Landscape
  3. 2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk
  4. Novel treatments for familial hypercholesterolemia: PharmacogenetiCs At Work
  5. Novel treatments for familial hypercholesterolemia: Pharmacogenetics at work
  6. Aspirin for cardioprotection and strategies to improve patient adherence.
  7. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia
  8. PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers
  9. The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction
  10. Update on strategies to increase HDL quantity and function.
  11. Potent and selective PPAR-α agonist LY518674 upregulates both apoA-I production and catabolism in human subjects with the metabolic syndrome
  12. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
  13. Endocannabinoid Antagonism: Blocking the Excess in the Treatment of High-Risk Abdominal Obesity
  14. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport
  15. High-density lipoprotein cholesterol therapies: The next frontier in lipid management
  16. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome
  17. Drugs in development: Targeting high-density lipoprotein metabolism and reverse cholesterol transport